SEC Fines Biopharma Co. Execs Over Hidden FDA Findings
By Sydney Price · January 16, 2026, 8:40 PM EST
Former executives of Spero Therapeutics will pay over $187,000 to settle the U.S. Securities and Exchange Commission's claims they downplayed the likelihood that the U.S. Food and Drug Administration would reject...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login